Proliferative activity of cancer stem cells in the prognosis of hematogenous metastasis of colon adenocarcinoma

A. A. Erokhina; Ерохина А. А.; V. S. Chirsky; Чирский В. С.; N. A. Maistrenko; Майстренко Н. А.; A. A. Sazonov; Сазонов А. А.; S. G. Grigorev; Григорьев С. Г.

doi:10.23868/202209006

Proliferative activity of cancer stem cells in the prognosis of hematogenous metastasis of colon adenocarcinoma

作者: Erokhina A.A.¹, Chirsky V.S.¹, Maistrenko N.A.¹, Sazonov A.A.¹, Grigorev S.G.¹
隶属关系:
1. S.M. Kirov Military Medical Academy
期: 卷 17, 编号 2 (2022)
页面: 40-46
栏目: Original Study Articles
URL: https://journals.rcsi.science/2313-1829/article/view/143492
DOI: https://doi.org/10.23868/202209006
ID: 143492

如何引用文章

全文:

开放存取

##reader.subscriptionAccessGranted##
受限制的访问

订阅存取

详细
全文:
作者简介
参考
补充文件
统计

详细

The search for prognostic markers to determine the risk of dissemination and metastasis of colon adenocarcinoma is one of the most difficult and actual problems of modern oncomorphology.The aim of this work was to determine the possibility of using indicators of the proliferative activity of cancer stem cells in the prediction of hematogenous metastasis of colon adenocarcinoma.

In this work the surgical material from 32 radically operated patients of different ages suffering from a localized colon adenocarcinoma was explored, and relapse-free survival was assessed. A comparative analysis of various components of the tumor differon, including proliferating stem cells and their relationship with the formation of relapse was carried out.An index of stem cell proliferation was proposed to assess the influence of stem cell activity on the biological behavior of tumor.

The best rates of relapse-free survival were found in the group of patients with low value of the index of stem cell proliferation compared with patients which index took on high values, which is more typical for elderly and old patients. With a similar comparison of other indicators of tumor differon, including the percentage of ALDH1 and Ki-67-positive cells, as well as cells with the ALDH1⁺Ki-67⁺immenophenotype relative to the total tumor differon, no significant relationship with relapse-free survival was found.

These results may indicate a high role of ALDH1⁺ cell proliferation in tumor dissemination, especially in elderly and senile patients, and a lesser influence of both the proliferative activity of Ki-67 and the general population of stem cells on the formation of distant metastases.

关键词

colorectal adenocarcinoma, stem cells, cancer stem cells, disease-free survival

全文:

##article.viewOnOriginalSite##

参考

GLOBOCAN Database 2020 [Электронный ресурс], https://gco.iarc.fr/.
Мерабишвили В.М., Щербук Ю.А. Онкологическая служба в Санкт-Петербурге и в районах города в 2008 году: заболеваемость, смертность, выживаемость. Ежегодник популяционного ракового регистра 2009; 240–1 [Merabishvili V.M., Shcherbuk Yu.A. Cancer service in St. Petersburg and in the city districts in 2008: morbidity, mortality, survival. Population Cancer Registry Yearbook 2009; 240–1].
Демидов С.М., редактор. Стадирование. В: Демидов С.М., редактор. Колоректальный рак и рак прямой кишки: учебное пособие. Екатеринбург, Российская Федерация: УГМУ; 2016. с. 11–12 [Demidov C.M., editor. Grading. In: Demidov C.M., editor. Colorectal cancer and rectal cancer: textb. allowance. Ekaterinburg, Russia: UGMU; 2016. p. 11–12].
Майстренко Н.А., Хватов А.А., Сазонов А.А. Хирургическое лечение больных пожилого и старческого возраста с местно-распространенным раком толстой кишки. Вестник хирургии им. И.И. Грекова 2016; 175(4): 24–31 [Maistrenko N.A., Khvatov A.A., Sazonov A.A. Surgical treatment for patients of elderly and senile age with locally advanced colon cancer. Grekov’s bulletin of surgery 2016; 175(4): 24–31].
Раскин Г.А., Петров С.В. Низкий уровень пролиферации — неблагоприятный прогностический признак при аденокарциноме толстой кишки. Казанский мед. ж. 2014; 95(3): 378–82. [Raskin G.A., Petrov S.V. Low proliferative level is a poor prognostic factor for colon adenocarcinoma. Kazan Med. J. 2014; 95(3): 378–82].
Fluge O., Gravdal K., Carlsen E. et al. Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. Br.J. Cancer 2009; 101(8): 1282–9.
Hayashi H., Beppu T., Sakamoto Y. et al. Prognostic value of Ki-67 expression in conversion therapy for colorectal liver-limited metastases. Am.J. Cancer Res. 2015; 5(3): 1225–33.
Deng Y., Zhou J., Fang L. et al. ALDH1 is an independent prognostic factor for patients with stages II-III rectal cancer after receiving radiochemotherapy. Br.J. Cancer 2014; 110(2): 430–4.
Goossens-Beumer I.J., Zeestraten E.C.M., Benard A. et al. Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer. Br.J. Cancer. Nature Publishing Group 2014; 110(12): 2935–44.
Chen J., Xia Q., Jiang B. et al. Prognostic value of cancer stem cell marker ALDH1 expression in colorectal cancer: A systematic review and meta-analysis. PLoS One 2015; 10(12): 1–15.
Harada N., Mizoi T., Kinouchi M. et al. Introduction of antisense CD44s cDNA down-regulates expression of overall CD44 isoforms and inhibits tumor growth and metastasis in highly metastatic colon carcinoma cells. International Journal of Cancer 2000; 91(1): 67–75.
Dallas M.R., Liu G., Chen W. et al. Divergent roles of CD44 and carcinoembryonic antigen in colon cancer metastasis. FASEB J. 2012; 26(6): 2648–56.
Ершов В.А., Михайлов В.М., Чирский В.С. Резервные и базальные клетки эпителия шейки матки как источник цервикальных неоплазий, ассоциированных с вирусом папилломы человека. Гены и Клетки 2019; 14(1): 80–4 [Ershov V.A., Mikhailov V.M., Chirsky V.S. Reserve and basal cells of epithelia of cervix uteri as a source of cervical neoplasies by human papilloma viruses. Genes and Сells 2019; 14(1): 80–4].
Magni M., Shammah S., Shiro R. et al. Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood 1996; 87(3): 1097–103.
Dylla S.J., Beviglia L., Park I. et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 2008; 3(6): 1–13.